Artelo Biosciences
Steven Kelly has served on our Board of Directors since May 2017. He brings nearly thirty years of experience in Pharma/Biotech at all phases of the business across multiple therapeutic categories. Mr. Kelly is currently CEO at Carisma Therapeutics, a venture backed biotech pioneering the development of CAR macrophages, a disruptive approach to immunotherapy in cancer. Previously, Mr. Kelly was the founding CEO of Pinteon Therapeutics, an early stage oncology and CNS development company. Prior to this he held a number of leadership positions in the biotechnology industry including: CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen. Mr. Kelly holds a BS from the University of Oregon and an MBA from Cornell University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Artelo Biosciences
Modulating the endocannabinoid system is among the most promising fields in the pharmaceutical industry. At Artelo Biosciences, we’re applying true biopharma discipline toward developing and commercializing a diverse portfolio of novel therapeutic cand...